Coya Therapeutics (COYA) Projected to Post Earnings on Monday

Key Points

• Coya Therapeutics is set to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.22) per share.
• Shares recently increased by 0.8% to $6.14 and have a market cap of $102.72 million.
• Several analysts have issued ratings on Coya Therapeutics, with a consensus price target of $16.50 and a range of buy ratings from $14.00 to $18.00.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Coya Therapeutics to post earnings of ($0.22) per share for the quarter.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, meeting the consensus estimate of ($0.44). The firm had revenue of $257.88 million during the quarter, compared to analysts' expectations of $2.63 million. On average, analysts expect Coya Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coya Therapeutics Stock Down 0.3%

Shares of Coya Therapeutics stock traded down $0.02 during mid-day trading on Friday, hitting $6.08. The stock had a trading volume of 14,985 shares, compared to its average volume of 73,859. The firm has a 50-day moving average of $5.93 and a two-hundred day moving average of $6.07. Coya Therapeutics has a 12-month low of $4.65 and a 12-month high of $10.24. The firm has a market cap of $101.72 million, a P/E ratio of -5.68 and a beta of 0.26.

Hedge Funds Weigh In On Coya Therapeutics

A hedge fund recently raised its stake in Coya Therapeutics stock. Jane Street Group LLC lifted its stake in Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 101.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 26,137 shares of the company's stock after acquiring an additional 13,176 shares during the quarter. Jane Street Group LLC owned 0.16% of Coya Therapeutics worth $169,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 39.75% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on COYA shares. Wall Street Zen cut shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Chardan Capital reissued a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Tuesday, July 1st. Lake Street Capital started coverage on shares of Coya Therapeutics in a research note on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price target for the company. D. Boral Capital reissued a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Thursday, July 24th. Finally, HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, June 9th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.